Drugs /

maraba oncolytic virus expressing mutant hpv e6/e7

Back to Drugs List

Overview

NCI Definition [1]:
A cancer vaccine comprised of a recombinant, attenuated form of the oncolytic rhabdovirus Maraba (MG1) encoding inactive, mutant forms of the human papillomavirus (HPV) transforming proteins E6 and E7, with potential immunostimulating and antineoplastic activities. Upon administration of MG1-E6E7, MG1 preferentially infects tumor cells and induces the expression of the E6 and E7 proteins. The MG1 virus exerts its oncolytic activity, thereby directly lysing tumor cells. Following the lysis of infected cells, the virus is released and can infect adjacent cells, which both induces further tumor cell oncolysis and may activate the immune system to kill the infected tumor cells. The expressed E6 and E7 proteins stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV E6 and E7, thereby further inducing tumor cell lysis. Oncoproteins E6 and E7 play a key role in the development of cervical intraepithelial neoplasia (CIN) and cervical carcinoma.

Clinical Trials

View Clinical Trials for maraba oncolytic virus expressing mutant hpv e6/e7

Maraba oncolytic virus expressing mutant hpv e6/e7 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating maraba oncolytic virus expressing mutant hpv e6/e7, 1 is phase 1 (1 open).

CDKN2A Overexpression and HPV Positive are the most frequent biomarker inclusion criteria for maraba oncolytic virus expressing mutant hpv e6/e7 clinical trials.

Anal carcinoma, cervical carcinoma, and oropharyngeal carcinoma are the most common diseases being investigated in maraba oncolytic virus expressing mutant hpv e6/e7 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Maraba Oncolytic Virus Expressing Mutant Hpv E6/e7
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating maraba oncolytic virus expressing mutant hpv e6/e7 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
oncolytic virus mg1-e6e7, oncolytic mg1 virus-encoding e6e7, mg1-expressing mutant hpv e6/e7, mg1-e6e7, mg1-e6/e7
NCIT ID [1]:
C157776

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.